In 2022 our group has pushed forward in the laboratory three main areas of research with the corresponding financial support and intellectual protection of the results: (i) use of radiogenomics and artificial intelligence to accurately discriminate between indolent and aggressive prostate cancer (PCa); (ii) study of new strategies to improve PCa diagnosis and management of BRCA-2 carriers (both from a clinical and molecular perspective); (iii) study of key mitotic regulators with a relevant role in resistance to hormone therapy and their potential as new therapeutic targets for treating the most aggressive tumors (with a focus on kinases and co-regulators, kinesins and ubiquitin ligases). We have generated models of primary cultures ex vivo and studied the mechanisms of progression and resistance to therapy. We have enlarged our collection of PCa liquid biopsies and tissues and provided with some of these samples to Joaquin Mateo’s group at VHIO for collaborative PDXs collection.

Group Leader
Joan Morote Robles, Anna Santamaria Margalef

Principal Investigator (PI)
Olga Méndez, Enric Trilla

Researchers
Jacques Planas, Mercè Cuadras, Ana Celma, Lucas Regis, Inés de Torres, Maria Eugenia Semidey

PhD Students
Marta Barber

Lab Technicians
David Ruiz

Nursing and Technical Staff
Lidia Ramírez, master student

32

PUBLICATIONS

46.9%

%Q1

174

IMPACT FACTOR

5.43

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Bradbury M, Borràs E, Castellví J, Méndez O, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Sabidó E, Santamaria A.
BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.
Sci Rep. 2022 Mar 15;12(1):4445
DOI: doi: 10.1038/s41598-022-08461-0
IF: 4.996

Morote J, Borque-Fernando Á, Triquell M, Campistol M, Celma A, Regis L, Abascal JM, Servian P, Planas J, Méndez O, Esteban LM, Trilla E.
A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand.
Cancers (Basel). 2022 Oct 18;14(20):5100
DOI: doi: 10.3390/cancers14205100
IF: 6.575

Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Escobar M, Mast R, de Torres IM, Semidey ME, Abascal JM, Sola C, Servian P, Salvador D, Santamaría A, Planas J, Esteban LM, Trilla E.
The Barcelona Predictive Model of Clinically Significant Prostate Cancer.
Cancers (Basel). 2022 Mar 21;14(6):1589
DOI: doi: 10.3390/cancers14061589
IF: 6.575

Salazar A, Regis L, Planas J, Celma A, Santamaria A, Trilla E, Morote J.
A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy.
Eur Urol Oncol. 2022 Aug;5(4):460-463.
DOI: doi: 10.1016/j.euo.2021.02.005
IF: 8.512

Morote J, Campistol M, Celma A, Regis L, de Torres I, Semidey ME, Roche S, Mast R, Santamaría A, Planas J, Trilla E.
The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.
World J Mens Health. 2022 Apr;40(2):270-279.
DOI: doi: 10.5534/wjmh.210117
IF: 6.494

Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la quinesina KIF11 (PI17/02248)
Principal Investigator: Juan Morote
Agency: Instituto de Salud Carlos III
Funding: 100,000 €
Period: 2018-2020 (prolonged until June 2022)

Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence (PI20/01666)
Principal Investigator: Juan Morote
Agency: Instituto de Salud Carlos III
Funding: 151,250 €
Period: 2021-2023

Red Federada de Inteligencia Artificial para acelerar la Investigación Sanitaria (MIA.2021.M02.0005).
Principal Investigator: Anna Santamaria Margalef
Agency: Ministerio de Asuntos Económicos y Transformación Digital
Funding: 987,624 €
Period: 2021-2024

Nuevas estrategias para la mejora del diagnóstico y el manejo terapéutico de los portadores de mutaciones en BRCA2 (PI21/00977)
Principal Investigator: Anna Santamaria Margalef
Agency: Instituto de Salud Carlos III
Funding: 159,720 €
Period: 2022-2024

INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY METHODS AND THERAPEUTIC COMBINATIONS
Priority Number: PCT/EP2020/069459 (WO2021005183)
Priority Date: 09/07/2020
Applicants: 47% VHIR/ 50% IQS /3% CIBERONC